Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sysmex Corporation

https://www.sysmex.co.jp/en/

Latest From Sysmex Corporation

Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers

Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.

Japan Regenerative Medicine

MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.

Commercial Sales & Earnings

New RWE Framework Aims To Get IVDs To Market Faster, Surveil COVID-19 Tests

Three years after the US FDA released a guidance to use real-world evidence in premarket applications, the stakeholder group MDIC has unveiled a framework for how IVD RWE can be captured and used by sponsors for premarket applications.

Regulation Research & Development

Start-Up Spotlight: Sight Diagnostics’ Imaging Technology Allows Accurate Diagnostics With Small Blood Samples

The US FDA recently cleared Sight’s Olo analyzer to run complete blood counts on samples as small as two drops. The company is currently marketing Olo to hospital labs in the US but hopes to eventually earn a CLIA waiver so Olo can be marketed to smaller physician practices and pharmacies and used for other common blood-based diagnostics.

Start-Up Spotlight In Vitro Diagnostics
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Other Names / Subsidiaries
    • D’PULA Medical Solutions Corporation
    • Oxford Gene Technology
    • RIKEN GENESIS
    • Sysmex Egypt LLC
    • Sysmex-Inostics
    • Sysmex Middle East FZ-LLC
    • TOA Medical Electronics Co., Ltd.
    • Medicaroid, Inc
    • Medicaroid Corporation
UsernamePublicRestriction

Register